KazakhstanTuberculosis profile
Population  2015 18 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.4 (1.1–1.7) 7.8 (6.3–9.5)
Mortality (HIV+TB only) 0.069 (<0.01–0.22) 0.39 (0.03–1.2)
Incidence  (includes HIV+TB) 16 (14–17) 89 (80–99)
Incidence (HIV+TB only) 0.5 (0.32–0.72) 2.8 (1.8–4.1)
Incidence (MDR/RR-TB)** 8.8 (7.1–10) 50 (40–57)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.63 (0.31–0.95) 5.6 (4.2–7.1) 6.3 (4.5–8)
Males 0.57 (0.34–0.79) 8.8 (7–11) 9.4 (7.3–11)
Total 1.2 (0.79–1.6) 14 (13–16) 16 (14–17)
TB case notifications, 2015  
Total cases notified 14 631
Total new and relapse 14 006
          - % tested with rapid diagnostics at time of diagnosis 83%
          - % with known HIV status 99%
          - % pulmonary 88%
          - % bacteriologically confirmed among pulmonary 81%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 89% (81–99)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.09 (0.07–0.12)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 376 3%
          - on antiretroviral therapy 275 73%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  4 000
(3 900–4 100)
Estimated % of TB cases with MDR/RR-TB 25% (24–26) 43% (42–45)  
% notified tested for rifampicin resistance 65% 95% 10 764
MDR/RR-TB cases tested for resistance to second-line drugs   6 237
Laboratory-confirmed cases MDR/RR-TB: 6 497, XDR-TB: 392
Patients started on treatment **** MDR/RR-TB: 6 948, XDR-TB: 391
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 90% 12 473
Previously treated cases, excluding relapse, registered in 2014 77% 330
HIV-positive TB cases, all types, registered in 2014 71% 381
MDR/RR-TB cases started on second-line treatment in 2013 72% 6 527
XDR-TB cases started on second-line treatment in 2013 30% 360
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 50%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
14% (13–15)
TB financing, 2016  
National TB budget (US$ millions) 119
Funding source: 100% domestic,  international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data